Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a notice addressed to stock exchanges regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes copies of newspaper advertisements. The document is short (1537 characters) and serves as an announcement of a regulatory action related to share transfers, not a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-27 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing that the promoters and promoter group of Indoco Remedies Limited have not made any encumbrance on their shares during the financial year 2022-2023. It references Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which pertains to disclosure of encumbrance of shares. The document includes a list of promoters and persons acting in concert. The content is a regulatory disclosure about share encumbrance status, not a financial report, management change, or voting result. It is a regulatory filing related to shareholding disclosures under SEBI regulations. The document length is short (2500 characters) and is a direct disclosure letter, not an announcement of a report or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-04-26 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2023-04-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window pursuant to SEBI regulations ahead of the declaration of audited financial results for the quarter and year ended March 31, 2023. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to insider trading restrictions before financial results are published. The document length is short (1651 characters), and it serves as a regulatory notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2023-03-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the appointment and re-appointment of Secretarial, Internal, and Cost Auditors for the financial year 2023-24. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The document does not contain financial statements or detailed financial analysis but is an announcement of auditor appointments. The length is 4577 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about auditor appointments and not a full audit report or annual report.
2023-03-29 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about a USFDA inspection at the company's manufacturing plants, mentioning Form 483 observations and the company's commitment to compliance. It is an informational announcement related to regulatory inspection results, not a full audit report or annual report. The document is short (1455 characters) and serves as a regulatory update to the exchanges. It does not contain financial data or detailed audit findings, so it is best classified as a Regulatory Filing (RNS).
2023-03-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.